Publications by authors named "Sawsan Rashdan"

Claim this Profile
A
Association of PD-L1 expression with systemic immune parameters in non-small cell lung cancer.
Mary E Gwin, Mitchell S von Itzstein, Jialiang Liu, Farjana J Fattah, Hong Mu-Mosley, Sawsan Rashdan

Transl Lung Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Profiling antigen-binding affinity of B cell repertoires in tumors by deep learning predicts immune-checkpoint inhibitor treatment outcomes.
Bing Song, Kaiwen Wang, Saiyang Na, Jia Yao, Farjana J Fattah, Sawsan Rashdan

Nat Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osimertinib plus consolidative radiotherapy for advanced mutant non-small cell lung cancer: a multicentre, single-arm, phase 2 trial.
Sagus Sampath, Sawsan Rashdan, Puneeth Iyengar, Townes A Mickel, Song Zhang

EClinicalMedicine· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Landscape and Management of Brain Parenchymal and Leptomeningeal Metastases in EGFR Mutated Non-Small Cell Lung Cancer.
Jonathan Hyak, Sawsan Rashdan

Cancers (Basel)· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming Financial and Access Barriers in Global Cancer Care With Low-Dose Immunotherapy: A Systematic Review.
Celine Hoyek, Binbin Zheng-Lin, Jennah J Bauernfeind, Omar Hussain Al-Ahmad, Tanios Bekaii-Saab, Sawsan Rashdan

JCO Glob Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and correlates of high-grade chemotherapy-induced peripheral neuropathy in patients with lung cancer.
Mitchell S von Itzstein, Sawsan Rashdan, Suzanne E Dahlberg, David E Gerber, Alan B Sandler

Oncologist· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concerning Safety and Efficacy of Concurrent and Consolidative Durvalumab With Thoracic Radiation Therapy in PDL1-Unselected Stage III Non-Small Cell Lung Cancer: Brief Report.
Yuanyuan Zhang, Puneeth Iyengar, Steven Montalvo, Kenneth D Westover, Sawsan Rashdan

Int J Radiat Oncol Biol Phys· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cmai: Predicting Antigen-Antibody Interactions from Massive Sequencing Data.
Bing Song, Kaiwen Wang, Saiyang Na, Jia Yao, Farjana J Fattah, Sawsan Rashdan

bioRxiv· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice.
Mitchell S von Itzstein, Yuqiu Yang, Yiqing Wang, David Hsiehchen, Thomas Y Sheffield, Sawsan Rashdan

Front Immunol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A review of perioperative treatment strategies with immunotherapy and tyrosine kinase inhibitors in resectable and stage IIIA-N2 non-small cell lung cancer.
Madeleine B Hopson, Sawsan Rashdan

Front Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
pan-MHC and cross-Species Prediction of T Cell Receptor-Antigen Binding.
Yi Han, Yuqiu Yang, Yanhua Tian, Farjana J Fattah, Mitchell S von Itzstein, Sawsan Rashdan

bioRxiv· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors.
Vatsala Mundra, Yuqiu Yang, Mitchell S von Itzstein, Farjana Fattah, Amrit S Gonugunta, Sawsan Rashdan

Transl Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The toxicity associated with combining immune check point inhibitors with tyrosine kinase inhibitors in patients with non-small cell lung cancer.
Anjali Kalra, Sawsan Rashdan

Front Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibiotic Prescriptions in Lung Cancer and Melanoma Populations: Differences With Potential Clinical Implications in the Immunotherapy Era.
Amrit S Gonugunta, Mitchell S Von Itzstein, David Hsiehchen, Tri Le, Sawsan Rashdan

Clin Lung Cancer· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential Impact of Revised NCI Eligibility Criteria Guidance: Prior Malignancy Exclusion in Breast Cancer Clinical Trials.
Matthew Perez, Caitlin C Murphy, Sandi L Pruitt, Sawsan Rashdan, Asal Rahimi

J Natl Compr Canc Netw· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Humoral and cellular correlates of a novel immune-related adverse event and its treatment.
Amrit S Gonugunta, Mitchell S von Itzstein, Hong Mu-Mosley, Farjana Fattah, J David Farrar, Sawsan Rashdan

J Immunother Cancer· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer.
Michael Burke, Sawsan Rashdan

Front Oncol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Narrative review: molecular and genetic profiling of oligometastatic non-small cell lung cancer.
Sawsan Rashdan, Puneeth Iyengar, John D Minna, David E Gerber

Transl Lung Cancer Res· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence and Significance of Potential Pharmacokinetic Drug-Drug Interactions Among Patients with Lung Cancer: Implications for Clinical Trials.
Sawsan Rashdan, Hui Yang, Tri Le, Christopher Selby, David E Gerber

Clin Drug Investig· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
QTc Interval-Prolonging Medications Among Patients With Lung Cancer: Implications for Clinical Trial Eligibility and Clinical Care.
Tri Le, Hui Yang, Sawsan Rashdan, Mark S Link, Vlad G Zaha

Clin Lung Cancer· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice.
Sawsan Rashdan, David E Gerber

Transl Lung Cancer Res· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy.
Sawsan Rashdan, John D Minna, David E Gerber

Lancet Respir Med· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A crowded, but still varied, space: brigatinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer.
Sawsan Rashdan, David E Gerber

Transl Cancer Res· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Going into BATTLE: umbrella and basket clinical trials to accelerate the study of biomarker-based therapies.
Sawsan Rashdan, David E Gerber

Ann Transl Med· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Salvage Therapy for Patients With Germ Cell Tumor.
Sawsan Rashdan, Lawrence H Einhorn

J Oncol Pract· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis